Sibylla Biotech tackles the intricacy of drug discovery using an innovative approach to address unmet medical requirements. Stemming from a scientific challenge, the PPI-FIT protocol (Pharmacological Protein Inactivation by Folding Intermediates Targeting) harnesses the groundbreaking capability of conducting atomistic protein folding pathways simulations to reveal a novel category of folding interfering degraders. Sibylla's pharmaceuticals are small-molecule protein degraders, and PPI-FIT is applicable across various therapeutic areas.